 |
|
|
|
 |
|
|
|
Full Program (tentative) |
|
|
|
| Oral |
Poster |
 |
 |
 |
 |
 |
 |
 |
Set-up: May 21 (Wed.) 17:00-19:00, May 22 (Thu.) 8:00-15:00
Presentation and Q&A |
| Basic Research (B43-171) |
: May 22 (Thu.) 17:00-18:00 |
| TR (TR29-127) |
: May 23 (Fri.) 17:00-18:00 |
| Clinical Study and Nursing (C24-93) |
: May 23 (Fri.) 17:00-18:00 |
|
|
|
|
|
Scientific Papers (Oral and Poster Presentations) |
|
- Basic research of neuroblastoma
- Translational research of neuroblastoma
- Clinical study of neuroblastoma
|
|
|
|
Invited Lectures |
|
| (1) Opening Lectures |
|
Alfred G. Knudson, Fox Chase Cancer Center, Philadelphia, USA |
|
|
"Themes of Hereditary Cancer in Children" |
|
Takashi Sugimura, National Cancer Center of Tokyo, JAPAN |
|
|
"Enjoyment of Science, Serendipitous Discovery, and Regrets of Dilettantism: Still Mysterious Mechanisms of Carcinogenesis" |
|
|
|
| (2) Plenary Lectures (four authorities from the related fields of neuroblastoma research) |
|
William G. Kaelin, Jr., Dana Farber Cancer Institute, Boston, USA |
|
|
"The von Hippel-Lindau Tumor Suppressor Gene: Potential Insights into Paraganglioma and Neuroblastoma" |
| |
Tatsutoshi Nakahata, Kyoto University, Japan |
|
|
"Therapeutic stem cell research (tentative)" |
|
Dale E. Bredesen, Buck Institute, San Francisco, USA |
|
|
"The Concept of Dependence Receptors" |
|
Patrick Mehlen, University of Lyon, France |
|
|
"The Dependence Receptor notion: When apoptosis regulates tumor progression and metastasis, from a cell biology concept to a putative targeted therapy in aggressive neuroblastoma" |
|
|
|
| (3) Educational Seminars |
|
Manfred Schwab, Heidelberg University, Germany |
|
|
"The MYCN story in neuroblastoma (tentative)" |
|
Susan L. Cohn & Andrew D. J. Pearson, USA & United Kingdom |
|
|
"International Neuroblastoma Risk Groups (INRG) (tentative)" |
|
Katherine K. Matthay, UCSF School of Medicine, USA |
|
|
"New Approaches to Neuroblastoma Therapy (NANT) consortium: Phase I Trials Targeting Neuroblastoma" |
|
Okio Hino, Juntendo University School of Medicine, Tokyo, Japan |
|
|
"Inazo Nitobe: The Soul of Japan" |
|
Bruno de Bernardi, Giannina Gaslini Children’s Hospital, Genova, Italy |
|
|
"SIOPEN (tentative)" |
|
Toshikazu Ushijima, National Cancer Center Research Institute, Tokyo, Japan |
|
|
"Epigenetics in Neuroblastomas" |
|
|
|
|
Workshops |
|
| (1) Translational OMICS in neuroblastoma |
|
Chairpersons:
|
Javed Khan, National Cancer Institute, USA
Miki Ohira, Chiba Cancer Center Research Institute, Japan |
|
Introduction:
Javed Khan, National Cancer Institute, USA |
|
Keynote:
Garrett Brodeur, Children's Hospital of Philadelphia, USA |
|
|
"History and significance of genomics in neuroblastoma (tentative)" |
| |
Invited talk:
Alea Mills, Cold Spring Harbor Laboratory, USA |
|
|
"CHD5 is a tumor suppressor mapping to human 1p36" |
|
Short talks:
John Maris, Children's Hospital of Philadelphia, USA |
|
|
"Genome whole association study (GWAS) of neuroblastoma (tentative)" |
| |
Jun Wei, National Cancer Institute, USA |
|
|
"microRNA profiling and function in Pediatric Cancers" |
|
Jo Vandesompele, Center for Medical Genetics, Ghent University Hospital, Belgium |
|
|
"Real-time PCR based profiling of prognostic gene signatures" |
| |
Miki Ohira, Chiba Cancer Center Res. Inst., Japan |
|
|
"Prognosis classification of neuroblastoma by genetic and genomic approaches" |
| |
Alexander Schramm, University Children's Hospital Essen, Germany |
|
|
"Proteomics: From high-throughput technology to target validation" |
| |
Discussion: |
|
|
|
|
| (2) Neuroblastoma Stem Cell |
|
Chairpersons: |
David Kaplan, Hospital for Sick Children, Toronto, Canada
Frank Speleman, Ghent University Hospital, Ghent, Belgium
Takehiko Kamijo, Chiba Cancer Center Res. Inst., Chiba, Japan |
|
Keynote:
David Kaplan, Hospital for Sick Children, Toronto, Canada |
|
|
"Do cancer stem cells exist in neuroblastoma?" |
| |
Invited talk:
Hideki Enomoto, MD, PhD, Riken Center for Developmental Biology, Kobe, Japan |
|
|
"Genetic analysis of RET signaling in neural development and neurocristopathy" |
|
Short talks:
Takehiko Kamijo, Chiba Cancer Centre Research Institute, Chiba, Japan |
|
|
"MYCN regulates stemness-related gene expression in neuroblastoma" |
|
Amy McKee, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA |
|
|
"A high frequency of tumor-initiating cells with stem cell properties persists in established neuroblastoma cell lines" |
|
Nicole Gross, University Hospital, CHUV, Lusanne, Switzerland |
|
|
"Identification of neuroblastoma specific stem cells markers by micro-array time-course analysis of neurospheres" |
|
Hedwig Deubzer, German Cancer Research Center, Heidelberg, Germany |
|
|
"Identification of neuroblastoma stem cells" |
|
Frank Speleman, Ghent University Hospital, Ghent, Belgium |
|
|
"Normal fetal neuroblast and cancer stem cell profiling" |
|
Discussion: |
|
|
|
| (3) Translational Targeting Therapies Against High-risk Neuroblastomas |
|
Chairpersons: |
Patrick Reynolds, Children's Hospital, Los Angeles, USA
Murray Norris, Children’s Cancer Institute, Australia
Simone Fulda, Children’s Hospital, Ulm University, Germany |
|
Consortia on Preclinical Testing:
John Maris, Children's Hospital of Philadelphia |
|
|
Pediatric Preclinical Testing Program (PPTP): what is new for neuroblastoma |
|
Andy Pearson, The Institute of Cancer Research |
|
|
SIOPEN Strategy for Neuroblastoma Drug Development leading to the Druggable Cancer Genome |
|
Experimental therapeutics:
Olaf Witt, German Cancer Research Center |
|
|
HDAC inhibitors |
|
Per Kogner, Karolinska Institute |
|
|
Cox, Lox and mTOR inhibition |
|
Patrick Reynolds, Children's Hospital, Los Angeles |
|
|
Fenretinide |
|
Michael Hogarty, Children's Hospital of Philadelphia |
|
|
ODC as molecular target |
|
David Kaplan, The Hospital for Sick Children MaRs Centre |
|
|
Targeting neuroblastoma stem cells |
|
Roundtable discussion:
- What are the most promising targets?
- What are the best preclinical models to evaluate experimental therapeutics?
- Cancer stem cells: are we currently hitting the right target and what models do we need to develop therapeutics that target cancer stem cells?
- Is developing a drug specifically for neuroblastoma feasible: how would such a drug be funded in development and beyond and what would be the strategy to obtain regulatory approval? Would a focus on drugs that also have potential for indications beyond be neuroblastoma be preferred?
|
|
|
|
|
Other Meetings |
|
| ANR Adv Board Meeting |
|
Date: |
May 21, 2008 |
|
Time: |
20:00-22:00 |
|
Place: |
Room 202 |
|
|
|
| WG-1 International Neuroblastoma Risk Groups (INRG) (by invitation) |
|
Date: |
May 21, 2008 |
|
Time: |
8:00 -11:30 |
|
Place: |
Room A |
|
|
|
| WG-2 International Neuroblastoma Tissue Banks (INTB) (by invitation) |
|
Date: |
May 23, 2008 |
|
Time: |
17:00 - 18:00 |
|
Place: |
Room D |
|
|
|
| SG-1 ANR2008-Nurses |
|
Date: |
May 22, 2008 |
|
Time: |
15:30 -17:00 |
|
Place: |
Room 202 |
|
|
|
| SG-2 International Neuroblastoma Pathological Classification (INPC) (by invitation) |
|
Date: |
May 23, 2008 |
|
Time: |
14:00 -16:00 |
|
Place: |
Room D |
|
|
|
|
|
# 2008 International Open Symposium on Childhood Cancer Survivorship
May 24, 2008 13:30 - 16:30 Conventional Hall |
|
 TOP |
|
|
|
|
|
